Monatide (IMS 3015) clinical trials
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2005
How each study uses Monatide (IMS 3015) is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2005 (1)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 3
Dana-Farber Cancer Institute (1) · Sellas Life Sciences Group (1) · NYU Langone Health (1) · Dr. Nina Bhardwaj (1) · Cytos Biotechnology AG (1)
Often tested with
Tested in the same studies.
Ipilimumab (1) · Galinpepimut-s (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Peptides (1) · Dendritic Cell (1) · Melan-A VLP Vaccine (1) · CYT004 (1)
Studies
Open first, then newest update. How each study uses Monatide (IMS 3015) is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced MelanomaActive, not recruitingPhase 1Dana-Farber Cancer InstituteNCT03929029Written as NeoVax plus Montanide
- Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality TherapyCompletedPhase 2Sellas Life Sciences GroupNCT01265433Written as Galinpepimut-S + Montanide + GM-CSF
- Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide in Patients With CNS TumorsCompletedPhase 1NYU Langone HealthNCT00935545Written as Montanide
- Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma VaccineCompletedPhase 1Dr. Nina BhardwajNCT00124124Written as KLH, peptides plus Montanide
- Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma PatientsCompletedPhase 2Cytos Biotechnology AGNCT00651703Written as CYT004-MelQbG10 + Montanide
Given beside what is tested · 3 — Monatide (IMS 3015) is usual care or a partner of the new treatment
- Peptide Vaccinations to Treat Patients With Low-Risk Myeloid CancersCompletedPhase 2National Heart, Lung, and Blood Institute (NHLBI)NCT00488592Written as Montanide adjuvant
- Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic CancerStatus unknownPhase 1Benovus Bio, Inc.NCT02240537Written as Montanide
- Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid NeoplasmsCompletedNot applicableH. Lee Moffitt Cancer Center and Research InstituteNCT00665002Written as Montanide
Codes
What other systems call Monatide (IMS 3015) · ClinicalTrials.gg INT001491
- MeSH (NLM) C000712049Monatide (IMS 3015)One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000712049 | Monatide (IMS 3015) | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.